HEMATOLOGY

CT071, a chimeric antigen receptor T-cell therapy candidate, had an investigational new drug application cleared by the FDA for patients with relapsed/refractory multiple myeloma and primary plasma cell leukemia.

A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.

A glimpse into the ever-changing treatment landscape of DLBCL, exploring frontline therapy options and the potential for tailoring treatments based on novel agents and randomized trials.

Dr. Lunning explores the FDA-approved CD3- and CD20-targeting bispecifics in relapsed/refractory DLBCL, highlighting their potential impact on heavily pretreated patients.

A comprehensive exploration of CAR T-cell therapy and additional agents such as loncastuximab in relapsed/refractory DLBCL, emphasizing clinical findings and treatment considerations.

A deep dive into the use of Polatuzumab Vedotin in DLBCL treatment, including insights from clinical trials and innovative strategies.

Matthew Lunning, DO, FACP, further explores relapsed/refractory DLBCL treatment strategies and clinical trial findings from the L-MIND and RE-MIND2 studies, discussing the impact of tafasitamab + lenalidomide on patient outcomes.

An in-depth examination of relapsed/refractory DLBCL treatment options, including CAR T-cell therapy and tafasitamab, based on clinical trial data and patient eligibility.

Expert insights into a 67-year-old man's journey through relapsed/refractory diffuse large B-cell lymphoma, exploring diagnosis, treatment options, and outcomes.

During a Targeted Oncology™ Case-Based Roundtable™ event, Uma Borate, MBBS, moderated discussion of physicians' familiarity with diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm. This is the second of 2 articles based on this event.

As a monotherapy, bispecific antibodies have demonstrated antitumor activity in heavily pretreated patients with B-cell and T-cell hematologic malignancies, but much work is needed to determine the optimal setting.

Vijaya Raj Bhatt, MBBS, MS, discusses background and findings from a multicenter, phase 2 study of ruxolitinib for the treatment of patients with steroid refractory sclerotic chronic graft-versus-host disease.

Explores the intricate decision-making process for frontline treatment in BPDCN patients, with considerations for age, fitness, and various therapeutic approaches.

Expert insight into the diagnostic markers and challenges of BPDCN, including the importance of involving dermatologists and pathologists, to identify various disease presentations in both adult and pediatric patients.

Matthew Ulrickson, MD, discusses a patient case of BPDCN, emphasizing the importance of recognizing and treating this rare disease, exploring various treatment options, and highlighting the evolving prognosis.

With a partial clinical hold in place, patient enrollment must halt in the phase 1 NX-2127-001 trial.

In the fourth article of this series, Amer Zeidan, MBBS, MHS, reviews recent data in lower-risk myelodysplastic syndrome and discusses the evolving treatment landscape.

Allogeneic transplant is, today, a curative therapy for a variety of blood cancers, including many cases of acute monocytic leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes.

Hetty Carraway, MD, MBA, discusses treatment with tagraxofusp and allogeneic stem cell transplant for patients with blastic plasmacytoid dendritic cell neoplasm.

In an interview with Targeted Oncology, Courtney DiNardo, MD, MSCE, discussed what oncologists should know about ivosidenib and the drug’s potential in treating hematologic malignancies.

A study published in the Journal of the American College of Cardiology found that chimeric antigen receptor T-cell therapy was associated with fewer major cardiac events than previously thought. 

Ivosidenib tablets have received FDA approval for the treatment of adult patients with relapsed/refractory myelodysplastic syndromes with a susceptible IDH1 mutation.

During a Targeted Oncology™ Case-Based Roundtable™ event, Uma Borate, MBBS, asked physicians about their experiences with patients with hematological malignancies with skin manifestations, and how to diagnose and work up these patients. This is the first of 2 articles based on this event.

A novel CD20xCD3 bispecific antibody showed promising safety and preliminary antitumor activity in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Dan T. Vogl, MD, MSCE, discusses the mechanism of action of modakafusp alfa for the treatment of patients with relapsed or refractory multiple myeloma.

James Foran, MD, offers valuable insights on recognizing and treating blastic plasmacytoid dendritic cell neoplasm, emphasizing the importance of early diagnosis, collaboration with specialists, and staying informed about therapeutic advances.

Expert perspectives on the sequencing of treatment options for blastic plasmacytoid dendritic cell neoplasm, considering patient age, response to tagraxofusp, venetoclax-based therapies, clinical trials, and future possibilities for targeted agents.

Expert perspectives on the sequencing of treatment options for blastic plasmacytoid dendritic cell neoplasm, considering patient age, response to tagraxofusp, venetoclax-based therapies, clinical trials, and future possibilities for targeted agents.

A key opinion leader identifies the clinical manifestations and diagnostic markers of blastic plasmacytoid dendritic cell neoplasm, shedding light on its presentation and diagnostic significance in real-world medical settings.

A review of diagnostic challenges and comprehensive workup, including CD markers, cytogenetics, and next-generation sequencing, for patients with blastic plasmacytoid dendritic cell neoplasm, a rare and unique acute leukemia.